About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Seattle | 515 Studies

Clinical Trials LymphomaSeattle

Lymphoma Clinical Trials in Seattle

Find 515 clinical trials for lymphoma near Seattle, Washington. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Seattle

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 515 trials

CompletedRituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin LymphomaThis phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL).NCT00244855·Seattle, Washington CompletedSafety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsThis Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R)…NCT05225584·Orange, California and 12 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedPNT2258 for Treatment of Patients With Richter's Transformation (Brighton)This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to…NCT02378038·Orange, California and 8 others

CompletedLaboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic LeukemiaThis phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia…NCT01865617·Seattle, Washington

Active not recruitingTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasThis phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual…NCT03984448·Birmingham, Alabama and 633 others

CompletedA Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaThis is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of ABT-199 under a once daily dosing schedule.NCT01328626·Tucson, Arizona and 9 others

TerminatedEnzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaThis pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to…NCT02489123·Seattle, Washington

TerminatedA Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLThis is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell…NCT03547115·Duarte, California and 11 others

CompletedSirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantThis phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing…NCT01251575·Denver, Colorado and 4 others

CompletedA Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesThe purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic…NCT00051597·Birmingham, Alabama and 9 others

CompletedStudy of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaThis study is being conducted to identify how much and how often pralatrexate, given with vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell…NCT00554827·Duarte, California and 9 others

RecruitingEvaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaThis clinical trial evaluates the effects of hemoglobin threshold-specific packed red blood cell (PRBC) transfusions on quality of life and functional outcomes in patients who…NCT06710418·Seattle, Washington

CompletedS0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00376961·Anchorage, Alaska and 146 others

CompletedStudy of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyThe primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab…NCT00877006·Tucson, Arizona and 127 others

CompletedA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaThis is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL.NCT02594384·Huntsville, Alabama and 10 others

TerminatedPhase 1b Safety and Efficacy Study of TRU-016The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and…NCT01644253·Augusta, Georgia and 7 others

CompletedBlood Samples to Evaluate Biomarkers of Donor ChimerismWe are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants.NCT00764829·Seattle, Washington

TerminatedStudy of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)This study has 3 parts.NCT01925612·Phoenix, Arizona and 50 others

RecruitingThis is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaThis study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the…NCT07121946·Duarte, California and 5 others

TerminatedTreatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaThe purpose of this randomized, open-label study is to evaluate the safety and efficacy of denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide)…NCT02592876·Little Rock, Arkansas and 28 others

Page 1 of 26Next

Other Conditions in Seattle

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia